AHA 2021: EMPATROPISM FE: Effects of Empagliflozin on Iron Metabolism in Non-diabetic HF Patients

Подробнее о видео

Watch the full video on Radcliffe Cardiology here:

Prof Christiane E Angermann (University Hospital of Würzburg, Würzburg, DE) discusses a substudy of the EMPATROPISM Randomized Trial. The trial found that Empagliflozin administration to nondiabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo. the substudy, presented at AHA 21, looks into the effects of Empagliflozin on iron metabolism in non-diabetic patients with heart failure.

Discussion Points:
1. Background for the Study
2. Unanswered Questions in Relation to the Mechanism of SGLT2is
3. Design and Patient Population
4. What Has Iron to Do With HF and Cardiac Function?
5. Key Results
6. Clinical Implications
7. Take-Home Messages
8. Next Step

Recorded remotely from Würzburg, 2021.

This content is intended for healthcare professionals only.

Radcliffe Cardiology is a dynamic, digitally-focused producer & publisher of Cardiovascular, Renal and Metabolic (CVRM) content for physicians worldwide. We aim to assist in the continuous education of physicians within the cardiology fraternity, generating a range of clinical content through collaboration with leading cardiologists from around the globe.